Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 17/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.47 |
| ▸ | KIT | P10721 | 4/20 | 0.46 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | CSF1R | P07333 | 3/20 | 0.46 |
| ▸ | LYN | P07948 | 3/20 | 0.46 |
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 3/20 | 0.46 |
| ▸ | BLK | P51451 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161468 | 0.91 | DGAT1 (0.42) | NPC1MAPTRAB9ASMN1; SMN2PKM | |
| SCHEMBL15022085 | 0.90 | DGAT1 (0.55) | NPC1MAPTRAB9ASMN1; SMN2PKM | |
| SCHEMBL163071 | 0.88 | DGAT1 (0.44) | NPC1MAPTRAB9ASMN1; SMN2KDR | |
| SCHEMBL173286 | 0.87 | KDR (0.49) | NPC1MAPTRAB9ASMN1; SMN2PKM | |
| SCHEMBL162774 | 0.87 | DGAT1 (0.43) | MAPTDGAT1NTRK1 | |
| SCHEMBL161553 | 0.87 | DGAT1 (0.59) | NPC1MAPTRAB9ASMN1; SMN2PKM | |
| SCHEMBL162781 | 0.86 | DGAT1 (0.47) | MAPTSMN1; SMN2KDRTEKDGAT1 | |
| SCHEMBL162339 | 0.86 | MAPT (0.42) | MAPTPKMKDRFLT3AURKA | |
| SCHEMBL164678 | 0.86 | DGAT1 (0.56) | NPC1MAPTRAB9ASMN1; SMN2DGAT1 | |
| SCHEMBL162085 | 0.85 | DGAT1 (0.53) | KDRPDGFRBKITAURKATEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | NPC1 86/4885MAPT 137/4885RAB9A 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.